Cargando…

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease

OBJECTIVE: To identify regional brain metabolic dysfunctions associated with neuropsychiatric symptoms (NPS) in preclinical Alzheimer disease (AD). METHODS: We stratified 115 cognitively normal individuals into preclinical AD (both amyloid and tau pathologies present), asymptomatic at risk for AD (e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Kok Pin, Pascoal, Tharick A., Mathotaarachchi, Sulantha, Chung, Chang-Oh, Benedet, Andréa L., Shin, Monica, Kang, Min Su, Li, Xiaofeng, Ba, Maowen, Kandiah, Nagaendran, Rosa-Neto, Pedro, Gauthier, Serge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5419982/ https://www.ncbi.nlm.nih.gov/pubmed/28404803 http://dx.doi.org/10.1212/WNL.0000000000003916

Ejemplares similares

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease
por: Ng, Kok Pin, et al.
Publicado: (2021)

Characterizing biomarker features of cognitively normal individuals with ventriculomegaly
por: Li, Xiaofeng, et al.
Publicado: (2017)

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia
por: Therriault, Joseph, et al.
Publicado: (2018)

Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals
por: Ng, Kok Pin, et al.
Publicado: (2021)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia
por: Ng, Kok Pin, et al.
Publicado: (2019)

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)

CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem
por: Benedet, Andréa L., et al.
Publicado: (2018)

Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
por: Ba, Maowen, et al.
Publicado: (2016)

Targeting Alzheimer’s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment
por: Gauthier, Serge, et al.
Publicado: (2018)

VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis
por: Mathotaarachchi, Sulantha, et al.
Publicado: (2016)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia
por: Savard, Melissa, et al.
Publicado: (2022)

Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum
por: Ng, Kok Pin, et al.
Publicado: (2022)

In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
por: Pascoal, T A, et al.
Publicado: (2017)

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment
por: Pascoal, Tharick A., et al.
Publicado: (2020)

Amyloid‐dependent and amyloid‐independent effects of Tau in individuals without dementia
por: Therriault, Joseph, et al.
Publicado: (2021)

Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
por: Wang, Yi-Ting T, et al.
Publicado: (2021)

Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
por: Ng, Kok Pin, et al.
Publicado: (2017)

Role of Cognitive Enhancer Therapy in Alzheimer’s Disease with Concomitant Cerebral White Matter Disease: Findings from a Long-Term Naturalistic Study
por: Ng, Kok Pin, et al.
Publicado: (2014)

Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic
por: Kang, Min Su, et al.
Publicado: (2021)

Epistasis analysis links immune cascades and cerebral amyloidosis
por: Benedet, Andréa L., et al.
Publicado: (2015)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

Imaging Alzheimer's disease pathophysiology with PET
por: Schilling, Lucas Porcello, et al.
Publicado: (2016)

APOEε4 potentiates the relationship between amyloid-β and tau pathologies
por: Therriault, Joseph, et al.
Publicado: (2020)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Aβ-induced vulnerability propagates via the brain’s default mode network
por: Pascoal, Tharick A., et al.
Publicado: (2019)

Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
por: Schaffer Aguzzoli, Cristiano, et al.
Publicado: (2023)

Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images
por: Sharafi, Sayed Mehran, et al.
Publicado: (2019)

Topology of diffusion changes in corpus callosum in Alzheimer's disease: An exploratory case-control study
por: Kumar, Sumeet, et al.
Publicado: (2022)

Corrigendum: Topology of diffusion changes in corpus callosum in Alzheimer's disease: An exploratory case-control study
por: Kumar, Sumeet, et al.
Publicado: (2023)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Hypometabolism as a therapeutic target in Alzheimer's disease
por: Costantini, Lauren C, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1r2emdedp5uccdvq1480k8o65i